Literature DB >> 8108314

Effects of simvastatin and pravastatin on 6 beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A.

Y Horsmans1, J P Desager, V van den Berge, M Abrassart, C Harvengt.   

Abstract

The influence of two inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, simvastatin and pravastatin, on the level of urinary 6 beta-hydroxycortisol/17-hydroxycorticosteroids (6 beta-OHC/17-OHCS) ratio was determined in two groups of normolipidemic Caucasian subjects (n = 18 and n = 14, respectively). The 6 beta-OHC/17-OHCS ratio increased significantly after simvastatin administration (20 mg day-1 for 17 days) (P = 0.0125) whereas no modification was observed after pravastatin administration (20 mg day-1 during 17 days). As the level of 6 beta-OHC/17-OHCS ratio is a function of cytochrome P-450 3A activity, these results suggest that in Caucasian subjects, simvastatin but not pravastatin could be a weak inducer of cytochrome P-450 3A. This contrasting effect could be related to the major pharmacological differences existing between these two drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8108314     DOI: 10.1006/phrs.1993.1127

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

1.  Successful Treatment with Colesevelam HCl and Pravastatin in a Patient Previously Hospitalised with Severe Normal CPK Myopathy on Introduction of Simvastatin.

Authors:  John D Moore
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 2.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

3.  The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity.

Authors:  Janne Hukkanen; Johanna Puurunen; Tuulia Hyötyläinen; Markku J Savolainen; Aimo Ruokonen; Laure Morin-Papunen; Matej Orešič; Terhi Piltonen; Juha S Tapanainen
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 5.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

6.  Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes.

Authors:  Kazutaka Sakamoto; Makoto Osaki; Akira Hozumi; Hisataka Goto; Tatsuya Fukushima; Hideo Baba; Hiroyuki Shindo
Journal:  BMC Musculoskelet Disord       Date:  2011-04-27       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.